Healthcare · Pharmaceuticals & Biotechnology
QVM read Quality in motion Quality Strong, Valuation Expensive, Momentum Bullish
Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.
RPG Life Sciences (RPGLS) is an Indian pharmaceutical company. Formerly known as Searle (India) Ltd, RPG Life Sciences is part of RPG Enterprises. It has its corporate office in RPG House in Worli, Mumbai. Its three major activities are the manufacturing and marketing of bulk drugs, also known as active pharmaceutical ingredients (API); pharmaceutical formulation; and fermentation and biotechnology. RPGLS is present in the domestic as well as the international market. It exports its products primarily to Europe, Latin America, Australia and South East Asian countries.
Source: Wikipedia
Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.
PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.
Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.
Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.
Ranks #60 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.
| Filed | Person | Category | Type | Quantity | Value |
|---|---|---|---|---|---|
| 26 Dec 2024 | Nucleus Life Trust | Promoter group | Buy | 0 | ₹0 |
| 24 Dec 2024 | Nucleus Life Trust | Promoter group | Buy | 0 | ₹0 |
| 24 Dec 2024 | Nucleus Life Trust | Promoter group | Buy | 0 | ₹0 |
| 24 Dec 2024 | Nucleus Life Trust | Promoter group | Buy | 0 | ₹0 |
| 24 Dec 2024 | Nucleus Life Trust | Promoter group | Buy | 0 | ₹0 |
| 20 Dec 2024 | Nucleus Life Trust | Promoter group | Buy | 0 | ₹0 |
| 20 Dec 2024 | Nucleus Life Trust | Promoter group | Buy | 0 | ₹0 |
| 18 Dec 2024 | Nucleus Life Trust | Promoter group | Buy | 0 | ₹0 |
| 18 Dec 2024 | Nucleus Life Trust | Promoter group | Buy | 0 | ₹0 |
| 16 Dec 2024 | Nucleus Life Trust | Promoter group | Buy | 0 | ₹0 |
| Date | Client | Deal | Action | Quantity | Price | Exchange |
|---|---|---|---|---|---|---|
| 30 Apr 2026 | NK SECURITIES RESEARCH PRIVATE LIMITED | Bulk | Buy | 109,801 | 2257.0200 | NSE |
| 30 Apr 2026 | NK SECURITIES RESEARCH PRIVATE LIMITED | Bulk | Sell | 109,801 | 2258.7300 | NSE |
| 21 Sep 2021 | XTX MARKETS LLP | Bulk | Sell | 136,929 | 731.4700 | NSE |
| 21 Sep 2021 | XTX MARKETS LLP | Bulk | Buy | 135,708 | 730.5300 | NSE |
| 3 Sep 2021 | XTX MARKETS LLP | Bulk | Buy | 89,624 | 596.0000 | NSE |
| 3 Sep 2021 | XTX MARKETS LLP | Bulk | Sell | 85,613 | 597.0800 | NSE |
| 1 Sep 2021 | XTX MARKETS LLP | Bulk | Buy | 162,323 | 566.9100 | NSE |
| 1 Sep 2021 | XTX MARKETS LLP | Bulk | Sell | 159,973 | 568.0900 | NSE |
| 6 Jan 2020 | M/S MENTOR CAPITAL LIMITED | Bulk | Sell | 327,584 | 294.3100 | NSE |
| 6 Jan 2020 | AUTHUM INVESTMENT & INFRASTRUCTURE LIMITED | Bulk | Buy | 327,584 | 294.3100 | NSE |
| Ex-date | Subject | Per share (₹) | Record date |
|---|---|---|---|
| 9 Jul 2026 | Dividend - Rs 24 Per Share | 24.0000 | 9 Jul 2026 |
| 27 Jun 2025 | Dividend - Rs 20 Per Share/ Special Dividend - Rs 4 Per Share | 20.0000 | 27 Jun 2025 |
| 28 Jun 2024 | Dividend - Rs 16 Per Share | 16.0000 | 28 Jun 2024 |
| 21 Jul 2023 | Dividend - Rs 12 Per Share | 12.0000 | 21 Jul 2023 |
| 14 Jul 2022 | Dividend - Rs 9.60 Per Share | 9.6000 | 15 Jul 2022 |
| 13 Aug 2021 | Dividend - Rs 7.20 Per Share | 7.2000 | 17 Aug 2021 |
| 24 Mar 2020 | Interim Dividend - Rs 4 Per Share | 4.0000 | 26 Mar 2020 |
| 22 Jul 2019 | Annual General Meeting/ Dividend - Rs 2.40 Per Share | 2.4000 | — |
| 19 Jul 2018 | Annual General Meeting/Dividend- Rs 2.40 Per Share | 2.4000 | — |
| 13 Jul 2017 | Annal General Meeting/Dividend - Rs 2.80 Per Share | 2.8000 | — |
Bonuses, splits, buybacks and other events. Dividends are listed separately above.
| Ex-date | Type | Subject |
|---|---|---|
| — | NAME_CHANGE | Name changed from RPG Life Sciences Limited` to RPG Life Sciences Ltd |
| — | NAME_CHANGE | Name changed from Searle (India) Ltd to RPG Life Sciences Ltd |
| 19 Jul 2016 | OTHER | Annual General Meeting |
| 30 Jul 2009 | AGM | Agm/Div-Rs.1.20 Per Share |
Quarterly results, AGMs, buybacks and other board-approved business.
| Date | Purpose | Results |
|---|---|---|
| 28 Jul 2026 | Financial Results | Yes |
| 29 Apr 2026 | Financial Results/Dividend | Yes |
| 27 Jan 2026 | Financial Results | Yes |
| 17 Oct 2025 | Financial Results | Yes |
| 25 Jul 2025 | Financial Results | Yes |
Exchange disclosures (NSE and BSE), most recent first.
| Date | Category | Announcement |
|---|---|---|
| 30 Sep 2026 | Company Update | RPG Life Sciences Ltd - 532983 - Announcement under Regulation 30 (LODR)-Newspaper Publication |
| 30 Sep 2026 | Copy of Newspaper Publication | Newspaper advertisement in respect to Special window opened for lodgment of transfer and dematerialization request(s). |
| 28 Sep 2026 | Insider Trading / SAST | RPG Life Sciences Ltd - 532983 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 |
| 26 Sep 2026 | General Updates | RPG Life Sciences Limited has informed the Exchange about General Updates |
| 25 Sep 2026 | Trading Window | RPG Life Sciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 |
| 25 Sep 2026 | Insider Trading / SAST | RPG Life Sciences Ltd - 532983 - Closure of Trading Window |
| 24 Sep 2026 | General Updates | Update on share purchase agreement dated July 29, 2026, with Actis Generics Private Limited |
| 23 Sep 2026 | Spurt in Volume | Significant increase in volume has been observed in RPG Life Sciences Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. RPG Life Sciences Limited has submitted their response. |
| 23 Sep 2026 | Spurt in Volume | Significant increase in volume has been observed in RPG Life Sciences Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited. |
| 17 Sep 2026 | Analysts/Institutional Investor Meet/Con. Call Updates | RPG Life Sciences Limited has informed the Exchange about Schedule of meet |
Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.
Data unavailable.
Data unavailable.
Board of directors and corporate information →
Data unavailable (no single-stock futures or options activity on record for this company).
The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.
The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.
The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.
No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.
